Kalliope D. Smalios, ARNP

Kalliope Smalios practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Kalliope Smalios' NPI, 1366988511, was assigned on January 12, 2017. Kalliope Smalios holds Florida license ARNP 9349994.

Kalliope Smalios' primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Kalliope Smalios' primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Kalliope Smalios to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Kalliope Smalios practices, 2 sites in all. Vendor and product names are available with a free account.

Family is Kalliope Smalios' primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Kalliope Smalios is licensed in Florida.

CMS data shows 306 Medicare services from Kalliope Smalios across 5 procedure codes in 2024, for 120 Medicare patients. Medicare paid $14,318 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 120 Medicare patients who saw Kalliope Smalios in 2024. The largest group is 65 to 74, with 67 patients. 75% of them have high blood pressure, and 72% have high cholesterol. Their average risk score is 3.40, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Kalliope Smalios' median patient age at 69, with 45% women.

In 2024, Kalliope Smalios wrote 214 Medicare Part D claims for 65 patients. 93% of them were for generic drugs. CMS names the drug for 87 of them, across 2 drugs with 11 or more claims each, at $1,173 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Kalliope Smalios for performance year 2024, reported as part of a group. Kalliope Smalios accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Kalliope Smalios from 2 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $116.